CDKN2A and Alzheimer disease: Further, selective clearing of p16‐expressing cells with a genetic approach or removing senescent cells with senolytic compounds in AD mouse models have been shown to ameliorates various aspects of AD pathologies including tau phosphorylation, NFTs formation, Aβ load, and cognitive decline (Bussian et al. 2018; Hu et al. 2021; Musi et al. 2018; Zhang et al. 2019).